medcelerator · clinician one-pager

First EU Medicine for Early Brain ALD in Boys Ages 2–12

Nezglyal (leriglitazone) — oral suspension for early cerebral adrenoleukodystrophy (Gd-negative)

EMA Authorised · European Union · September 25, 2026

Condition: Cerebral Adrenoleukodystrophy

Who this is for

This is for boys aged 2 to 12 with early cerebral adrenoleukodystrophy (cALD) — Gd-negative brain lesions on MRI and a Neurological Functional Score of 0 or 1 — and the caregivers helping them. It explains the European Commission marketing authorisation for Nezglyal (leriglitazone) oral suspension on 21 September 2026 under exceptional circumstances, how once-daily height- and weight-based dosing works from the SmPC, what NEXUS (MT-2-02) showed about arrested disease, and how to ask an ALD / leukodystrophy specialist about labelled EU supply versus HSCT timing — without claiming US or Canadian approval, treating open-label evidence as a cure, or importing an EU bottle. Authorized is not funded.

Next clinical step

The European Union has authorised this medicine, on the advice of the European Medicines Agency (EMA). In the European Union, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.

Ways to access this treatment

European Union · Prescription
EU prescription (EC marketing authorisation)
https://www.ema.europa.eu/en/medicines/human/EPAR/nezglyal

General resources for further research

CTIS (EU Clinical Trials Information System)
European Union public portal for clinical trials submitted under the Clinical Trials Regulation. Search by medicine, condition, and member state. A CTIS record is not an EMA marketing authorisation and is not enrolment.
https://euclinicaltrials.eu/

AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/nezglyal-leriglitazone-cald